Applied Clinical Trials podcast

ACT Brief: Patient Trial Conversations, Measuring Site Burden, and Cosentyx and Wilserdly Approval

0:00
1:39
Rewind 15 seconds
Fast Forward 15 seconds
In today’s ACT Brief, we examine why oncologists should lead trial discussions while AI supports patients, how site burden can be measured before it becomes risk, and how FDA approved Cosentyx and Wilserdly for two different conditions.

More episodes from "Applied Clinical Trials"